Month: December 2020

CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) — BLGI, Inc. (OTCBB: BLGI) (“BLGI” or the “Company”) announced today the release of its new asset management trading platform.BLGI Markets (the “Platform”) has been designed and built by BLGI’s CEO Lawrence P. Cummins utilizing De-Centralized Network Architecture. “BLGI Markets will offer leading capabilities at significantly lower costs of entry and execution for our clients than existing competitor platforms available to the asset management industry. We look forward to seeing our partners and clients enjoy the benefits of many new capabilities within our latest release,” said Lawrence P. Cummins.The Platform provides real-time market data on company stocks, Forex, Futures, CFD’s EFT’s, Indices, Bitcoin, and Cryptocurrency Markets. A complete list can be found...

Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. Twirla is now available in the United States by prescription for women of reproductive potential with a body mass index (BMI) 35 years of age), smokers, and women with hypertension, dyslipidemia, diabetes, or obesity.Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment-Discontinue TWIRLA prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. TWIRLA can...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATESStrong Financial Growth AnticipatedPre- and Post-FID Investments Approved for Goldboro LNGHighlights:Net operating income (“NOI”)1 growth to $100-$130 millionAdjusted Funds Flow From Operations (“AFFO”)1 increase to $80-$110 millionAdjusted operating expenses1 of $9.50-10.50/boeProduction of 40,000-45,000 boe/d$45-55 million upstream capital budget$10-$15 million pre-FID Goldboro LNG development expense budget, and post-FID Goldboro LNG capital expenditure budget of $250-$350 million2Commodities hedging of 55-65% on an 18-month rolling boe/d basisCorporate and upstream general and administrative (“G&A”) costs of $0.90 to $1.00 per boe/dCALGARY, Alberta, Dec. 07, 2020 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”)...

53.8% ORR in relapsed/refractory DLBCL patientsPreliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a dose expansion study of tebotelimab, an investigational, bispecific PD-1 × LAG-3 DART® molecule, in patients with diffuse large B-cell lymphoma (DLBCL). The data were presented at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place December 5-8, 2020.LAG-3 has been shown to be highly expressed in DLBCL and has emerged as a therapeutic target of interest in this...

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.The company plans to work diligently with the FDA to address the agency’s questions and fulfill the requirements for resuming...

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations. In his most recent role, Mr. Muir was Director of Sales for the Embolics Interventional Oncology business unit of BTG plc where he played a key role in growing that business from $40 million to $180 million at which time BTG was acquired by Boston Scientific.Gerard Michel, CEO of Delcath, commented, “We are thrilled that Kevin is joining the Delcath team as VP of Commercial Operations. He is a seasoned and accomplished leader with experience across multiple innovative medical technologies with a recent focus in the growing field of interventional oncology....

SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor...

MANITOWOC, Wis., Dec. 07, 2020 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of LED lighting systems and turnkey project implementation, including installation and commissioning of fixtures, controls and IoT capabilities, ongoing system maintenance and program management, will present at the LD Micro Virtual Main Event Investor Conference on Monday, December 14th. Orion’s CEO Mike Altschaefl and CFO Per Brodin will give an introduction followed by addressing questions from an investor panel, beginning at 10:20am ET and ending at 10:40am ET.The LD Micro Virtual Main Event conference takes place December 14th and 15th and will feature over 250 small / micro-cap companies.To learn more or to register for the Main Event please visit: https://ve.mysequire.com/Chris Lahiji, Founder of LD, commented,...

TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (the “Company” or “Platinex“) has vested its option in the Skead-Ashley Option which is part of the Shining Tree property (the “Property” or “Shining Tree Gold Property”). The Shining Tree Gold Property is the largest holding in the Shining Tree gold district at 20,750 hectares (51,274 acres) situated along the Ridout-Tyrrell trend between the Juby deposit owned by Caldas Gold to the east and the mine development-stage Cote Gold deposit to the west owned by IAMGOLD.As a result of vesting its option Platinex now holds 100% interest subject to a 2% NSR royalty to Skead Holdings Ltd and Ashley Gold Mines Limited on a portion of its Property and also subject to a 3% NSR royalty in a separate agreement with Skead Holdings Ltd. on another portion...

ROCHESTER, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has partnered with Komodo Health, a data-driven healthcare software company with access to the broadest array of real-world data across patients, practitioners, and health systems. The partnership integrates Komodo’s comprehensive Healthcare Map with OptimizeRx’s digital health and communication platform to power OptimizeRx’s novel real-world evidence (RWE) solution. The solution leverages automated intelligence through machine-learning and APIs to seamlessly deliver point-of-care messaging.As the COVID-19 pandemic has demonstrated, prescribed therapies can change or evolve rapidly. Yet there are few channels currently available that can efficiently...